Compare IAC/Interactivecorp (PPLI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Recursion Pharmaceuticals Inc — how do they compare? IAC/Interactivecorp trades at $43.41 (market cap $3.28B), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: IAC/Interactivecorp is far larger — about 2× Recursion Pharmaceuticals Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PPLI | RXRX | |
|---|---|---|
Market Cap | $3.28B | $1.63B |
Sector | Media | Health |
52-Week High | $47.62 | $6.79 |
52-Week Low | $31.52 | $2.84 |
Enterprise Value | $3.58B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $44.09, down 0.99% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative EPS misses in recent quarters, though net income margin improved to -4.35% from -14.19% in 2024. Recent news highlights potential MGM acquisition talks and upcoming Q2 2026 earnings call on August 4th.
The stock presents a value opportunity with P/B of 0.73 and strong analyst support (63.6% buy rating, $55.40 consensus target), but faces execution risks from consecutive earnings misses and negative cash flow trends. Key catalysts include MGM deal progress and Q2 results, while competitive pressures and volatile profitability remain concerns.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
